Jinwon Life Sciences Announces Interim Clinical Results of MERS Vaccine at ASGCT Annual Meeting

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 29th that it has been selected as a presenter at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT), which will be held online between the 12th and 15th of next month, and plans to present the interim results of the Phase 1/2a clinical trial of the MERS vaccine GLS-5300.

The company stated, "The ASGCT annual meeting research presentation abstract book has been released, including an abstract presenting the interim results of the GLS-5300 Phase 1/2a clinical trial," adding, "Two doses of 0.6mg induced an 88% seroconversion rate, and neutralizing antibodies that suppress the MERS virus were confirmed in 92% of vaccine recipients."

In particular, it was explained that even a single vaccine dose induced binding antibodies in 74% of recipients and neutralizing antibodies in 48%, confirming the excellent vaccine immune response induction capability of GLS-5300 to effectively respond to MERS.

A company official also stated, "The presentation will be conducted by Dr. Christine Roberts, the clinical research lead at GeneOne Life Science, on May 14th at 4:45 PM Eastern Time, providing an opportunity to share clinical research data with academic experts and discuss the significance of the results."

GeneOne Life Science's GLS-5300 is a product jointly developed with Inovio and the International Vaccine Institute (IVI). It has received Phase 1/2a clinical trial approval from the Korea Food and Drug Administration and is conducting clinical research at Seoul National University Hospital and Bundang Seoul National University Hospital. The research funding is supported by the Samsung Life Public Welfare Foundation through the International Vaccine Institute.

This content was produced with the assistance of AI translation services.